{"id":1811,"date":"2013-11-22T00:00:00","date_gmt":"2013-11-22T00:00:00","guid":{"rendered":"http:\/\/www.neurodegenerationresearch.eu\/2013\/11\/second-amyloid-imaging-agent-approved-in-us-eu-approval-submitted\/"},"modified":"2014-09-22T09:14:44","modified_gmt":"2014-09-22T09:14:44","slug":"second-amyloid-imaging-agent-approved-in-us-eu-approval-submitted","status":"publish","type":"post","link":"https:\/\/neurodegenerationresearch.eu\/nb\/2013\/11\/second-amyloid-imaging-agent-approved-in-us-eu-approval-submitted\/","title":{"rendered":"Second amyloid imaging agent approved in US.  EU approval submitted"},"content":{"rendered":"<p><strong>The U.S. Food and Drug Administration on October 25 approved a second amyloid imaging agent. Flutemetamol is an F18-labeled ligand developed by GE Healthcare. It joins florbetapir, developed by Avid Pharmaceuticals\/Eli Lilly and Company. <\/strong><\/p>\n<p>Flutemetamol differs slightly from its cousin because it is approved to report the intensity of binding to amyloid plaques in false color. This could make scans easier to read, some experts agreed. The compound will be commercially available in early 2014. <\/p>\n<p>In regulatory terms, both are approved to indicate whether amyloid is present, and thereby support or refute an AD diagnosis. Neither is intended to diagnose AD on its own or replace other routine clinical tests for cognitive decline. Neither compound is approved to quantify amyloid plaques in the brain. That is something both companies are exploring. <\/p>\n<p>Both agents will be made available to both neurologists and researchers. GE Healthcare has submitted an application for approval to the European Medicines Agency (EMA), and will apply in various other countries in the coming months and years. Florbetapir has already gotten EMA approval, and Lilly\/Avid is seeking approval in other areas of the world.  <\/p>\n<p>Source:&amp;nbsp; AlzForum website &#8211; 21 Nov 2013<\/p>\n","protected":false},"excerpt":{"rendered":"<p>The U.S. Food and Drug Administration on October 25 approved [&hellip;]<\/p>\n<a href=\"https:\/\/neurodegenerationresearch.eu\/nb\/2013\/11\/second-amyloid-imaging-agent-approved-in-us-eu-approval-submitted\/\">View Post<\/a>","protected":false},"author":3,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[22],"tags":[],"class_list":["post-1811","post","type-post","status-publish","format-standard","hentry","category-research-news"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Second amyloid imaging agent approved in US. EU approval submitted - JPND Neurodegenerative Disease Research<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/neurodegenerationresearch.eu\/2013\/11\/second-amyloid-imaging-agent-approved-in-us-eu-approval-submitted\/\" \/>\n<meta property=\"og:locale\" content=\"nb_NO\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Second amyloid imaging agent approved in US. EU approval submitted - JPND Neurodegenerative Disease Research\" \/>\n<meta property=\"og:description\" content=\"The U.S. Food and Drug Administration on October 25 approved [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/neurodegenerationresearch.eu\/2013\/11\/second-amyloid-imaging-agent-approved-in-us-eu-approval-submitted\/\" \/>\n<meta property=\"og:site_name\" content=\"JPND Neurodegenerative Disease Research\" \/>\n<meta property=\"article:published_time\" content=\"2013-11-22T00:00:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2014-09-22T09:14:44+00:00\" \/>\n<meta name=\"author\" content=\"jpnd\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@JPNDeurope\" \/>\n<meta name=\"twitter:site\" content=\"@JPNDeurope\" \/>\n<meta name=\"twitter:label1\" content=\"Skrevet av\" \/>\n\t<meta name=\"twitter:data1\" content=\"jpnd\" \/>\n\t<meta name=\"twitter:label2\" content=\"Ansl. lesetid\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minutt\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/neurodegenerationresearch.eu\\\/2013\\\/11\\\/second-amyloid-imaging-agent-approved-in-us-eu-approval-submitted\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/neurodegenerationresearch.eu\\\/2013\\\/11\\\/second-amyloid-imaging-agent-approved-in-us-eu-approval-submitted\\\/\"},\"author\":{\"name\":\"jpnd\",\"@id\":\"https:\\\/\\\/neurodegenerationresearch.eu\\\/#\\\/schema\\\/person\\\/a97e49cae588ead81db59e48a4e63c2a\"},\"headline\":\"Second amyloid imaging agent approved in US. EU approval submitted\",\"datePublished\":\"2013-11-22T00:00:00+00:00\",\"dateModified\":\"2014-09-22T09:14:44+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/neurodegenerationresearch.eu\\\/2013\\\/11\\\/second-amyloid-imaging-agent-approved-in-us-eu-approval-submitted\\\/\"},\"wordCount\":205,\"publisher\":{\"@id\":\"https:\\\/\\\/neurodegenerationresearch.eu\\\/#organization\"},\"articleSection\":[\"Research News (General)\"],\"inLanguage\":\"nb-NO\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/neurodegenerationresearch.eu\\\/2013\\\/11\\\/second-amyloid-imaging-agent-approved-in-us-eu-approval-submitted\\\/\",\"url\":\"https:\\\/\\\/neurodegenerationresearch.eu\\\/2013\\\/11\\\/second-amyloid-imaging-agent-approved-in-us-eu-approval-submitted\\\/\",\"name\":\"Second amyloid imaging agent approved in US. EU approval submitted - JPND Neurodegenerative Disease Research\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/neurodegenerationresearch.eu\\\/#website\"},\"datePublished\":\"2013-11-22T00:00:00+00:00\",\"dateModified\":\"2014-09-22T09:14:44+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/neurodegenerationresearch.eu\\\/2013\\\/11\\\/second-amyloid-imaging-agent-approved-in-us-eu-approval-submitted\\\/#breadcrumb\"},\"inLanguage\":\"nb-NO\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/neurodegenerationresearch.eu\\\/2013\\\/11\\\/second-amyloid-imaging-agent-approved-in-us-eu-approval-submitted\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/neurodegenerationresearch.eu\\\/2013\\\/11\\\/second-amyloid-imaging-agent-approved-in-us-eu-approval-submitted\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/neurodegenerationresearch.eu\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Second amyloid imaging agent approved in US. EU approval submitted\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/neurodegenerationresearch.eu\\\/#website\",\"url\":\"https:\\\/\\\/neurodegenerationresearch.eu\\\/\",\"name\":\"JPND Neurodegenerative Disease Research\",\"description\":\"Neurodegenerative Disease Research\",\"publisher\":{\"@id\":\"https:\\\/\\\/neurodegenerationresearch.eu\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/neurodegenerationresearch.eu\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"nb-NO\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/neurodegenerationresearch.eu\\\/#organization\",\"name\":\"JPND\",\"url\":\"https:\\\/\\\/neurodegenerationresearch.eu\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"nb-NO\",\"@id\":\"https:\\\/\\\/neurodegenerationresearch.eu\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.neurodegenerationresearch.eu\\\/wp-content\\\/uploads\\\/2022\\\/03\\\/logo.png\",\"contentUrl\":\"https:\\\/\\\/www.neurodegenerationresearch.eu\\\/wp-content\\\/uploads\\\/2022\\\/03\\\/logo.png\",\"width\":248,\"height\":129,\"caption\":\"JPND\"},\"image\":{\"@id\":\"https:\\\/\\\/neurodegenerationresearch.eu\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/x.com\\\/JPNDeurope\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/neurodegenerationresearch.eu\\\/#\\\/schema\\\/person\\\/a97e49cae588ead81db59e48a4e63c2a\",\"name\":\"jpnd\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"nb-NO\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/b3244fc6099279fad29cb751cb709c5ee57befcda19ef0b44a4f0067989d7f7e?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/b3244fc6099279fad29cb751cb709c5ee57befcda19ef0b44a4f0067989d7f7e?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/b3244fc6099279fad29cb751cb709c5ee57befcda19ef0b44a4f0067989d7f7e?s=96&d=mm&r=g\",\"caption\":\"jpnd\"},\"url\":\"https:\\\/\\\/neurodegenerationresearch.eu\\\/nb\\\/author\\\/jpnd\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Second amyloid imaging agent approved in US. EU approval submitted - JPND Neurodegenerative Disease Research","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/neurodegenerationresearch.eu\/2013\/11\/second-amyloid-imaging-agent-approved-in-us-eu-approval-submitted\/","og_locale":"nb_NO","og_type":"article","og_title":"Second amyloid imaging agent approved in US. EU approval submitted - JPND Neurodegenerative Disease Research","og_description":"The U.S. Food and Drug Administration on October 25 approved [&hellip;]","og_url":"https:\/\/neurodegenerationresearch.eu\/2013\/11\/second-amyloid-imaging-agent-approved-in-us-eu-approval-submitted\/","og_site_name":"JPND Neurodegenerative Disease Research","article_published_time":"2013-11-22T00:00:00+00:00","article_modified_time":"2014-09-22T09:14:44+00:00","author":"jpnd","twitter_card":"summary_large_image","twitter_creator":"@JPNDeurope","twitter_site":"@JPNDeurope","twitter_misc":{"Skrevet av":"jpnd","Ansl. lesetid":"1 minutt"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/neurodegenerationresearch.eu\/2013\/11\/second-amyloid-imaging-agent-approved-in-us-eu-approval-submitted\/#article","isPartOf":{"@id":"https:\/\/neurodegenerationresearch.eu\/2013\/11\/second-amyloid-imaging-agent-approved-in-us-eu-approval-submitted\/"},"author":{"name":"jpnd","@id":"https:\/\/neurodegenerationresearch.eu\/#\/schema\/person\/a97e49cae588ead81db59e48a4e63c2a"},"headline":"Second amyloid imaging agent approved in US. EU approval submitted","datePublished":"2013-11-22T00:00:00+00:00","dateModified":"2014-09-22T09:14:44+00:00","mainEntityOfPage":{"@id":"https:\/\/neurodegenerationresearch.eu\/2013\/11\/second-amyloid-imaging-agent-approved-in-us-eu-approval-submitted\/"},"wordCount":205,"publisher":{"@id":"https:\/\/neurodegenerationresearch.eu\/#organization"},"articleSection":["Research News (General)"],"inLanguage":"nb-NO"},{"@type":"WebPage","@id":"https:\/\/neurodegenerationresearch.eu\/2013\/11\/second-amyloid-imaging-agent-approved-in-us-eu-approval-submitted\/","url":"https:\/\/neurodegenerationresearch.eu\/2013\/11\/second-amyloid-imaging-agent-approved-in-us-eu-approval-submitted\/","name":"Second amyloid imaging agent approved in US. EU approval submitted - JPND Neurodegenerative Disease Research","isPartOf":{"@id":"https:\/\/neurodegenerationresearch.eu\/#website"},"datePublished":"2013-11-22T00:00:00+00:00","dateModified":"2014-09-22T09:14:44+00:00","breadcrumb":{"@id":"https:\/\/neurodegenerationresearch.eu\/2013\/11\/second-amyloid-imaging-agent-approved-in-us-eu-approval-submitted\/#breadcrumb"},"inLanguage":"nb-NO","potentialAction":[{"@type":"ReadAction","target":["https:\/\/neurodegenerationresearch.eu\/2013\/11\/second-amyloid-imaging-agent-approved-in-us-eu-approval-submitted\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/neurodegenerationresearch.eu\/2013\/11\/second-amyloid-imaging-agent-approved-in-us-eu-approval-submitted\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/neurodegenerationresearch.eu\/"},{"@type":"ListItem","position":2,"name":"Second amyloid imaging agent approved in US. EU approval submitted"}]},{"@type":"WebSite","@id":"https:\/\/neurodegenerationresearch.eu\/#website","url":"https:\/\/neurodegenerationresearch.eu\/","name":"JPND Neurodegenerative Disease Research","description":"Neurodegenerative Disease Research","publisher":{"@id":"https:\/\/neurodegenerationresearch.eu\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/neurodegenerationresearch.eu\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"nb-NO"},{"@type":"Organization","@id":"https:\/\/neurodegenerationresearch.eu\/#organization","name":"JPND","url":"https:\/\/neurodegenerationresearch.eu\/","logo":{"@type":"ImageObject","inLanguage":"nb-NO","@id":"https:\/\/neurodegenerationresearch.eu\/#\/schema\/logo\/image\/","url":"https:\/\/www.neurodegenerationresearch.eu\/wp-content\/uploads\/2022\/03\/logo.png","contentUrl":"https:\/\/www.neurodegenerationresearch.eu\/wp-content\/uploads\/2022\/03\/logo.png","width":248,"height":129,"caption":"JPND"},"image":{"@id":"https:\/\/neurodegenerationresearch.eu\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/JPNDeurope"]},{"@type":"Person","@id":"https:\/\/neurodegenerationresearch.eu\/#\/schema\/person\/a97e49cae588ead81db59e48a4e63c2a","name":"jpnd","image":{"@type":"ImageObject","inLanguage":"nb-NO","@id":"https:\/\/secure.gravatar.com\/avatar\/b3244fc6099279fad29cb751cb709c5ee57befcda19ef0b44a4f0067989d7f7e?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/b3244fc6099279fad29cb751cb709c5ee57befcda19ef0b44a4f0067989d7f7e?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/b3244fc6099279fad29cb751cb709c5ee57befcda19ef0b44a4f0067989d7f7e?s=96&d=mm&r=g","caption":"jpnd"},"url":"https:\/\/neurodegenerationresearch.eu\/nb\/author\/jpnd\/"}]}},"_links":{"self":[{"href":"https:\/\/neurodegenerationresearch.eu\/nb\/wp-json\/wp\/v2\/posts\/1811","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/neurodegenerationresearch.eu\/nb\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/neurodegenerationresearch.eu\/nb\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/neurodegenerationresearch.eu\/nb\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/neurodegenerationresearch.eu\/nb\/wp-json\/wp\/v2\/comments?post=1811"}],"version-history":[{"count":0,"href":"https:\/\/neurodegenerationresearch.eu\/nb\/wp-json\/wp\/v2\/posts\/1811\/revisions"}],"wp:attachment":[{"href":"https:\/\/neurodegenerationresearch.eu\/nb\/wp-json\/wp\/v2\/media?parent=1811"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/neurodegenerationresearch.eu\/nb\/wp-json\/wp\/v2\/categories?post=1811"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/neurodegenerationresearch.eu\/nb\/wp-json\/wp\/v2\/tags?post=1811"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}